- Home
- CURR vs IOBT Comparison
CURR vs IOBT Comparison
Compare CURR & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- IOBT
- Stock Information
- Founded
- CURR 2013
- IOBT 2014
- Country
- CURR Singapore
- IOBT Denmark
- Employees
- CURR N/A
- IOBT N/A
- Industry
- CURR Business Services
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- IOBT Health Care
- Exchange
- CURR Nasdaq
- IOBT Nasdaq
- Market Cap
- CURR 74.0M
- IOBT 79.7M
- IPO Year
- CURR N/A
- IOBT 2021
- Fundamental
- Price
- CURR $0.43
- IOBT $1.29
- Analyst Decision
- CURR Strong Buy
- IOBT Strong Buy
- Analyst Count
- CURR 1
- IOBT 3
- Target Price
- CURR $3.50
- IOBT $9.33
- AVG Volume (30 Days)
- CURR 2.5M
- IOBT 233.4K
- Earning Date
- CURR 08-11-2025
- IOBT 08-12-2025
- Dividend Yield
- CURR N/A
- IOBT N/A
- EPS Growth
- CURR N/A
- IOBT N/A
- EPS
- CURR N/A
- IOBT N/A
- Revenue
- CURR $43,386,858.00
- IOBT N/A
- Revenue This Year
- CURR N/A
- IOBT N/A
- Revenue Next Year
- CURR $21.53
- IOBT N/A
- P/E Ratio
- CURR N/A
- IOBT N/A
- Revenue Growth
- CURR N/A
- IOBT N/A
- 52 Week Low
- CURR $0.33
- IOBT $0.66
- 52 Week High
- CURR $7.08
- IOBT $1.73
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- IOBT 49.63
- Support Level
- CURR N/A
- IOBT $1.26
- Resistance Level
- CURR N/A
- IOBT $1.57
- Average True Range (ATR)
- CURR 0.00
- IOBT 0.13
- MACD
- CURR 0.00
- IOBT -0.04
- Stochastic Oscillator
- CURR 0.00
- IOBT 19.46
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.